Who We Are
EyegenixTM is a regenerative medicine company developing a biosynthetic cornea for human transplantation that holds the promise to restore vision for an estimated 10 million people who suffer from corneal blindness.
Although corneal transplantation is a successful procedure that is performed more often than all other types of organ transplants combined, a lack of donors means that it currently helps less than 1% of patients with corneal blindness worldwide.
The Eyegenix biosynthetic cornea is unique in that it can replace a human donor with a completely synthetic, transplantable cornea designed to promote tissue repair, nerve regeneration, epithelialization—an off-the-shelf solution for patients worldwide.
The Eyegenix Biosynthetic Cornea
A Platform for Regenerative Medicine
The collagen-derived tissue from which the Eyegenix biosynthetic cornea is made also has the potential for broader application. It can be laser sculpted, with the potential to be used as a platform for refractive surgery.
But Eyegenix’s biocompatible product also addresses the medical trinity of tissue regeneration, allowing for nerve regeneration (which means the patient regains feeling and sensation); epithelialization (skin can grow over it, for tissue coverage); and tissue integration, which means that it can integrate into the patient’s own tissue to fill voids and defects left by surgery or trauma.
When these three things happen, human tissue can successfully be regenerated. The possibilities are endless, and include the future use of similar materials for breast reconstruction or other soft tissue repair following cancer surgery.